The in vitro susceptibilities of 11 strains of Chlamydia pneumoniae to azithromycin, clarithromycin, erythromycin, L-oflaxacin, and doxycycine were determined. Clarithromycin was the most active agent tested, with an MIC for 90% of strains and minimal chiamydiacidal concentration for 90%o of strains of 0.03 ,ug/ml. 
Chlamydia pneumoniae, the newly described chlamydial species, is emerging as a frequent cause of communityacquired respiratory tract infection, including pneumonia and bronchitis (4, 5) . There are limited data on the treatment of these infections, and what is available suggests that treatment with either erythromycin or doxycycline may not be very efficacious (5, 6) . Azithromycin, a new azalide antibiotic, and clarithromycin, a new macrolide, have attracted interest as potential therapy for community-acquired respiratory tract infection because they are active against a wide range of pathogens and have superior pharmacokinetics and tolerance compared with erythromycin (2, 12) . Preliminary studies from our laboratory with two clinical isolates of C. pneumoniae have demonstrated that clarithromycin and azithromycin are active in vitro against this organism (1) . The quinolone antibiotics also offer potential therapy for C. pneumoniae infections (7) . Ofloxacin is currently formulated as a racemic mixture; however, the levo isomer, L-ofloxacin, appears to be more active than the dextro form (3) . The purpose of this study was Data on the in vitro susceptibility of C. pneumoniae are limited, in part because of the small number of clinical isolates available for testing. Welsh et al. (13) reported MICs of azithromycin for C. pneumoniae of 0.06 to 1 ,ug/ml. They tested the prototype strain, TW183, and three clinical isolates from Seattle, Wash., and Atlanta, Ga. Treatment failure may be due to other factors, including inadequate tissue penetration and poor compliance due to side effects and prolonged duration of treatment. In this respect azithromycin and clarithromycin appear to offer potential advantages over erythromycin and doxycycline. The similar in vitro activities of azithromycin and erythromycin do not take into account azithromycin's prolonged half-life in serum and tissue (30 h in serum and .5 days in tissue) (12) . Azithromycin has been shown to be effective as a single 1-g dose for the treatment of uncomplicated C. trachomatis genital tract infection in men and nonpregnant women (9) . Azithromycin and clarithromycin have excellent tissue and intracellular penetration, especially into bronchial epithelium and alveolar macrophages (2, 12) . These observations suggest that both drugs may be superior to erythromycin for the treatment of respiratory infections due to C. pneumoniae. However, clarithromycin, despite lower MICs, will require multiple daily dosing and a longer duration of therapy compared with that of azithromycin. Clinical trials utilizing culture are clearly indicated.
The quinolones have also been demonstrated to be active against both C trachomatis and C. pneumoniae in vitro (7, 8) . Ofloxacin has an indication for the treatment of genital chlamydial infection and may be effective for respiratory infection with C. pneumoniae (8) . Ofloxacin is a racemic mixture, but L-ofloxacin has greater antimicrobial activity (11) . In animal studies, L-ofloxacin has exhibited more potent in vivo efficacy than ofloxacin, possibly due to its higher levels in serum and tissue penetration (3) . The activity in vitro was the same as we previously reported for ofloxacin (7) . Prospective clinical studies would be needed to demonstrate its superiority to ofloxacin.
